From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

BATS and GSK react to disappointments differently…

By Chris Bailey | Wednesday 26 April 2023


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I hope to have visited nicely over one hundred different countries before I go to a better place, but I reckon my chances of visiting North Korea are a bit light. I have been thinking about the country a few times over the last week for various reasons, but even I was surprised yesterday to read on British American Tobacco (BATS) an “agreement reached with DOJ and OFAC to resolve investigations into BAT's historical business activities in relation to North Korea from 2007-2017”.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Ariana – Surprise!

Time left: 08:48:50